Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study
This prospective Phase I/II study evaluated the long-term safety and efficacy of intravenous umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy combined with disease-modifying anti-rheumatic drugs (DMARDs) in 64 patients with rheumatoid arthritis (RA). Patients received 2 × 10⁷ UC-MSCs via intravenous infusion and were followed for up to 3 years.
June 26, 2025
No Comments